Sarilumab - Biologic Drug Details

Summary for sarilumab

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for sarilumab

Recent Clinical Trials for sarilumab

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Sanofi	PHASE4
Regeneron Pharmaceuticals	PHASE4
Eli Lilly and Company	PHASE3

See all sarilumab clinical trials

Pharmacology for sarilumab

Mechanism of Action	Interleukin 6 Receptor Antagonists
Established Pharmacologic Class	Interleukin-6 Receptor Antagonist

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for sarilumab Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for sarilumab Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Sanofi-aventis U.s. Llc	KEVZARA	sarilumab	Injection	761037	7,582,298		DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for sarilumab Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Sanofi-aventis U.s. Llc	KEVZARA	sarilumab	Injection	761037	10,111,968	2036-08-10	Patent claims search
Sanofi-aventis U.s. Llc	KEVZARA	sarilumab	Injection	761037	10,261,094	2034-10-30	Patent claims search
Sanofi-aventis U.s. Llc	KEVZARA	sarilumab	Injection	761037	10,369,114	2037-05-24	Patent claims search
Sanofi-aventis U.s. Llc	KEVZARA	sarilumab	Injection	761037	10,519,228	2039-05-08	Patent claims search

Sarilumab Market Analysis and Financial Projection

Last updated: February 13, 2026

What Are the Market Dynamics for Sarilumab?

Sarilumab, marketed as Kevzara by Sanofi and Regeneron, is a monoclonal antibody targeting interleukin-6 receptor (IL-6R), approved for rheumatoid arthritis (RA). It faces competition from other IL-6 inhibitors such as tocilizumab (Actemra/RoActemra) and emerging biologics targeting different cytokines.

Market Size and Growth Drivers

The global RA biologics market was valued at approximately $28 billion in 2022, with IL-6 inhibitors accounting for roughly 15% ($4.2 billion). Sarilumab's market share within this space fluctuates due to competition, regulatory preferences, and product positioning.

Key factors influencing demand include:

• Prevalence of RA: Estimated at 0.5% to 1% globally, affecting 15-20 million people.
• Unmet Needs: Patients with inadequate responses to TNF inhibitors seek alternative treatments, including IL-6 inhibitors.
• Physician Preference: Tocilizumab dominates the IL-6 class, comprising over 80% of IL-6 biologic prescriptions in some regions, limiting Sarilumab's expansion.
• Pricing and Reimbursement: Cost-effectiveness assessments influence clinician prescribing patterns; Sarilumab's pricing aligns with other biologics but faces reimbursements challenges in certain countries.
• Regulatory Decisions: Regulatory acceptance in China (approved in 2020) and Europe (approved in 2017) broadens potential market access.

Competitive Landscape

Sarilumab enters a crowded IL-6 inhibitor market. Tocilizumab is the leading product, with global sales exceeding $2.5 billion in 2022 (source: EvaluatePharma). Other competitors include sirukumab (not yet approved) and emerging biologics targeting different pathways.

Market penetration remains limited, with Sarilumab holding an estimated 4-5% share of the RA biologics market in 2022, constrained by physician familiarity with tocilizumab and formulary preferences.

Off-Label and Adjacent Markets

Potential expansion areas include:

• COVID-19 Cytokine Storm: Off-label use during the pandemic; recent clinical trials have yielded mixed results.
• Other Autoimmune Diseases: Investigations continue into sarilumab for juvenile idiopathic arthritis, giant cell arteritis, and other cytokine-driven conditions.

What Is the Financial Trajectory for Sarilumab?

Revenue Trends and Forecasts

Sanofi and Regeneron reported Sarilumab revenue of approximately $100 million in 2022. Sales are expected to grow at an annual rate of 5% to 8%, contingent on:

• Approval and uptake in European markets following earlier delays.
• Expansion into new indications and geographies.
• Uptake in developing countries with evolving biosimilar landscapes.

Cost Structure and Profitability

Manufacturing costs for monoclonal antibodies like Sarilumab are high, often constituting over 50% of expenses, including cell line development, production, and quality control. Pricing strategies are designed to balance market competitiveness with profitability.

Profit margins are sensitive to R&D investments, marketing expenses, and reimbursement policies. Currently, Sarilumab is not a high-margin product due to limited sales volume.

Pipeline and Developmental Outlook

Sanofi and Regeneron continue clinical development for Sarilumab in:

• COVID-19: Ongoing trials to evaluate efficacy.
• Other Conditions: Testing in psoriatic arthritis and Crohn’s disease.
• Combination Therapies: Assessing synergistic effects with other biologics.

Pipeline progress influences long-term financial prospects, with approval of novel indications potentially expanding revenue streams.

Market Risks and Opportunities

Risks include:

• Entry of biosimilars leading to price erosion.
• Regulatory delays or restrictions.
• Competition from other cytokine inhibitors.

Opportunities involve:

• Fast-tracking approvals for new indications.
• Strategic partnerships in emerging markets.
• Development of biosimilar versions to improve access and reduce costs.

Key Takeaways

• Sarilumab operates in the competitive IL-6 inhibitor segment with limited market share.
• The global RA biologics market is expanding, but Sarilumab's growth is constrained by entrenched competition.
• Revenue is modest, with a growth outlook tied to regulatory approvals and new indications.
• Cost structures are high; profitability depends on market penetration and pricing.
• Pipeline developments could influence long-term commercial prospects.

FAQs

Q1: How does Sarilumab compare with tocilizumab in efficacy?
A1: Head-to-head trials show comparable efficacy in RA, but clinician preference often favors tocilizumab due to vendor familiarity and earlier market entry.

Q2: What are the main barriers to Sarilumab's growth?
A2: Market dominance of tocilizumab, physician familiarity, reimbursement constraints, and limited geographic penetration.

Q3: Are biosimilars a threat to Sarilumab?
A3: Yes. Biosimilar versions of tocilizumab are available in some markets, potentially pressuring Sarilumab's pricing and market share.

Q4: Which regions hold growth potential?
A4: Europe remains key, with recent approvals in China and emerging markets offering expansion opportunities.

Q5: What is the outlook for Sarilumab in non-RA indications?
A5: Development in conditions like GCA and COVID-19 could diversify revenue streams, contingent on clinical success and regulatory approvals.

References

[1] EvaluatePharma. "Global Rheumatoid Arthritis Market Data," 2022.
[2] Sanofi. "Kevzara (Sarilumab) Prescribing Information," 2022.
[3] Regeneron Pharmaceuticals. "Financial Reports," 2022.
[4] World Health Organization. "Rheumatoid Arthritis Fact Sheet," 2022.